Rifasutenizol  (Synonyms: TNP-2198)

Rifasutenizol (TNP-2198) is a dual-targeted antibacterial agent that has a good antibacterial effect on Helicobacter pylori infection. Rifasutenizol can be used in the study of microaerophilic and anaerobic bacterial infections^[1].

Rifasutenizol exhibits potent bactericidal activity against key microaerophilic and anaerobic bacterial pathogens, including Helicobacter pylori, Clostridioides difficile, and Gardnerella vaginalis, including rifamycin-resistant and nitroimidazole-resistant strains^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

944.04

C₄₈H₆₁N₇O₁₃

1001314-13-1

Solid

Colorless to off-white

O=C(C)O[C@H]1[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C/C=C(C(NC(C(C2=C3C4=C(O[C@](C)(O/C=C/[C@H](OC)[C@H]1C)C4=O)C(C)=C2O)=O)=C5C3=NC6(CCN(CCN7C([N+]([O-])=O)=CN=C7C)CC6)N5)=O)/C

Room temperature in continental US; may vary elsewhere.

• [1]. Ma Z, et al. Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens. J Med Chem. 2022;65(6):4481-4495.  [Content Brief]

  [2]. Li X, et al. Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials[J]. The Lancet Infectious Diseases, 2024, 24(6): 650-664.  [Content Brief]